TLC announced the appointment of Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. Mr. Bliss joins TLC following interim roles in cellular therapy, drug delivery and combination therapy where he led efforts to confirm research outcomes and partner the various technologies.